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ABSTRACT
ObjectiveaaHuntington’s disease (HD) is a rare neurological disorder, and its current status in Korea is not well investigated. 
This study aims to determine the prevalence and incidence of HD and to investigate the clinical features of HD patients in Korea.
MethodsaaWe estimated the crude prevalence and annual incidence of HD based on the databases of the Rare Diseases Regis-
try (RDR) and the National Health Insurance (NHI). The clinical data of genetically confirmed HD patients was collected from 
10 referral hospitals and analyzed.
ResultsaaThe mean calculated annual incidence was 0.06 cases per 100,000 persons, and the mean calculated prevalence was 
0.38 based on the NHI database. The estimated crude prevalence based on the RDR was 0.41. Of the sixty-eight HD patients re-
cruited, the mean age of onset was 44.16 ± 14.08 years and chorea was most frequently reported as the initial symptom and chief 
complaint. The mean CAG repeat number of the expanded allele was 44.7 ± 4.8 and correlated inversely with the age of onset (p < 
0.001). About two-thirds of the patients have a positive family history, and HD patients without positive family history showed a 
delay in onset of initial symptoms, a prolonged interval between initial symptom onset and genetic diagnosis and a delay in the 
age of genetic diagnosis. 
ConclusionsaaTo the best of our knowledge, this is the first study to estimate the prevalence and incidence of HD in Korea and 
the largest HD series in the Asian population. Our analyses might be useful for further studies and large-scale investigations in 
HD patients.
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Huntington’s disease (HD) is a well-known neuro-
logical disorder of inherited genetic cause, the incur-
able nature of which has made patients and doctors 
helpless. Even after the discovery of the CAG repeat 
expansion of the IT-15 gene in 1993, no satisfactory 
treatment has emerged.1 In Korea, studies involving 
genetically confirmed HD patients were first pub-
lished from 1996, and the first clinical analysis was 
presented in 1997.2-5 These studies showed that there 
were a number of genetically confirmed HD patients 
without a family history of the disease, and also re-
vealed that caudate atrophy might be ambiguous 
even after several years of disease duration. Recent-
ly, decreased cortical glucose metabolism was sug-
gested as a predictor of disease progression in Ko-
rean patients with HD.6 However, the current status 
of HD in Korea requires additional investigation.
Huntington’s disease is an example of a rare dis-
ease, which are also referred to as rare and intracta-
ble diseases or orphan diseases, and are defined as 
affecting fewer than 20,000 people in Korea (Korean 
Centers for Disease Control and Prevention, 2006).7 
The Korean National Health Insurance (NHI) is a 
quasi-governmental organization supplying medical 
services for the entire Korean population, and its 
database contains a comprehensive dataset of its us-
ers. In July 2009, a nationwide registry for rare and 
intractable diseases (Rare Diseases Registry, RDR), 
was established by the Korean NHI in cooperation 
with the Ministry of Health and Welfare, and pa-
tients with HD have been registered in the RDR. 
The RDR database differs from the NHI database in 
that it gathers identifying information on each pa-
tient with a physician-certified diagnosis, making it 
possible to know the cumulative number of patients 
regardless of the usage of the NHI during a given 
period. Moreover, the annual incidence of diagnosis 
could be estimated by the number of newly regis-
tered patients with a given disease. To investigate 
the current status of HD in Korea, we collected data 
from 10 nationwide referral hospitals and used open 
data from the databases of the RDR and NHI. 
MATERIALS & METHODS
Data collection from the Korean Rare  
Diseases Registry and the National Health 
Insurance databases
We collected the data on HD patients who regis-
tered in the RDR between July 2009 and December 
2013. During this period, the total number of regis-
tered HD cases and the number of new registrations 
each year were identified. To estimate the preva-
lence of HD, the size of the Korean population in 
December 2013 was ascertained from resident reg-
istration data with respect to population data gath-
ered by the Korean Ministry of Security and Public. 
The annual incidence of HD from 2010 to 2013 was 
calculated based on the number of newly registered 
HD patients and the number of registered residents 
in December of the corresponding year. The Korean 
NHI database was used to crosscheck the preva-
lence of HD, based on the number of patients re-
ceiving medical care. 
Data collection from 10 referral hospitals 
around the country
For analysis of the clinical data of individual HD 
patients, medical records of 68 HD patients from 10 
referral hospitals around the country were reviewed. 
All patients had been diagnosed by a genetic test, 
which confirmed pathologically expanded CAG re-
peats at the HTT locus. There were no duplicate 
cases. The collected clinical data included patient 
demographics, the number of expanded and nor-
mal CAG repeats, initial symptoms and age of on-
set, the cause of the hospital visit (i.e., the chief com-
plaints), the date of the hospital visit for neurological 
examination, and the age at genetic diagnosis. There 
were sometimes multiple initial symptoms and chief 
complaints for a single patient. Depending on the 
age of initial symptoms, patients were categorized 
into juvenile-onset (i.e., HD before the age of 21 
years), adult-onset (21–59) and elderly (after 60 
years) according to the definition of juvenile-onset 
HD and the characteristic onset age of typical HD.8,9 
This research was approved by the Institutional Re-
view Board of CHA University.
Statistical analysis
The relationship between CAG repeat length and 
age at initial symptom onset was determined by non-
linear regression analysis. The differences associated 
with family history and the affected parental sex 
were compared by independent t test. All of the sta-
tistical analyses were performed using Predictive 
Analytics Software (version 21.0, IBM, New York, 
NY, USA).
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RESULTS
Crude prevalence and incidence of HD 
based on RDR and National Health  
Insurance databases (Table 1)
Excluding the HD patients registered in 2009 
when the RDR program began, the mean number 
of new patients registered annually between 2010 
and 2013 was 27.25 ± 7.14. Based on the resident 
registration data, the mean of calculated crude an-
nual incidences was 0.06 ± 0.01 cases per 100,000 
persons. The estimated crude prevalence of HD was 
0.41 cases per 100,000 persons, based on the cumu-
lative number of HD cases in the RDR database (n = 
208) and the size of the Korean population (n = 
51,141,463) as of December 2013. According to the 
NHI database, the mean number of HD patients re-
ceiving medical services annually between 2009 and 
2013 was 190.60 ± 19.86 (ranges from 171 to 222), 
with the mean percentage of males being 43.42 ± 
4.48%. The crude prevalence estimated based on the 
NHI database was 0.38 ± 0.04.
Analyses of HD patient data collected from 
10 referral hospitals around the country
Genetic analysis and clinical features (Table 2)
Sixty-eight HD patients, including 12 patients 
from six families, were recruited for this study. The 
mean number of CAG repeats of the expanded al-
lele was 44.7 ± 4.8. In normal alleles, the mean num-
ber of CAG repeats was 17.4 ± 3.2 without skewness 
in the distribution (data not shown). The number of 
CAG expansion showed an inverse correlation with 
the onset age of initial symptoms (R2 = 0.574, p-val-
ue < 0.001), and there was no correlation between 
the onset age of initial symptoms and the number of 
CAG repeats in normal allele (Figure 1). The mean 
age at initial symptom onset was 44.16 ± 14.08 years 
old, and the mean interval from initial symptom 
onset to the diagnosis of HD was 4.30 ± 2.96 years. 
Chorea (n = 41, 60.3%) was the most frequent initial 
symptom followed by psychiatric symptoms (n = 
19), gait disturbance (n = 13), dysarthria (n = 9), 
cognitive impairment (n = 8), parkinsonism (n = 2), 
and urinary symptom (n = 1). Causes of hospital 
visit (chief complaints) were chorea (n = 58, 85.3%), 
gait disturbance (n = 18), psychiatric symptoms (n = 
16), cognitive impairment (n = 12), dysarthria (n = 
Table 1. Number of HD patients according to the Korean RDR and NHI from 2009 to 2013
Year
Total Korean 
population
RDR NHI
New HD patients
Cumulative # 
of patients
Estimated 
incidence
Total # (male %)
Estimated 
prevalence
2009 49,773,145 99 99 NA 222 (50.5) 0.45
2010 50,515,666 36 135 0.07 182 (44.5) 0.36
2011 50,734,284 19 154 0.04 171 (42.7) 0.34
2012 50,948,272 25 179 0.05 181 (40.3) 0.36
2013 51,141,463 29 208 0.06 197 (39.1) 0.39
Total Korean population taken from resident registration data (December of each year). Estimated annual incidence = (incident cases 
per year / total Korean population) × 105, Estimated prevalence = (total cases per year / total Korean population) × 105. HD: Hunting-
ton’s disease, NA: not available, NHI: National Health Insurance, RDR: Rare Diseases Registry.
Table 2. Demographics and clinical characteristics of the patients, based on the collective data from 10 referral hospitals 
Clinical findings Number of patients or means ± SD Range
Sex (M:F) 41:27
Number of expanded CAG repeats 44.7 ± 4.8 37–60
Number of normal CAG repeats 17.4 ± 3.2 7–27
Family history (present:possible:absent) 43:4:21
Paternal:maternal 26:17
Age at initial symptom onset (year old)   44.16 ± 14.08 12–77
Age at genetic diagnosis (year old)   47.91 ± 14.42 17–80
Juvenile/adult/elderly 1/53/8
Interval from age at initial symptom onset to age  
  at genetic diagnosis (years)
  4.30 ± 2.96 1–10
Interval from chief complaints appearance to hospital visit (months)   33.53 ± 28.99   1–120
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10), parkinsonism (n = 4), tremor (n = 3), limb atax-
ia (n = 2), dysphagia (n = 1), and dystonia (n = 1). 
The age at initial symptom onset was identified in 62 
patients, among whom there was 1 juvenile-onset 
patient (1.6%) and 8 elderly-onset patients (12.8%). 
The occupations of 50 patients (73.5%) were classi-
fied based on the Korean standard classification of 
occupations with the addition of several categories 
such as “no employment” and “housewife”. There 
was no significant correlation between HD diagno-
sis and occupation (Figure 2). 
Comparisons according to the family history 
(Table 3)
Positive family history of HD was found in 43 pa-
tients (63.2%), with paternal transmission occurring 
in 26 patients (60.5%) and maternal transmission in 
17 patients (39.5%). In 21 patients (30.9%), there was 
no identifiable family history. Four patients had 
possible family histories, having had family mem-
bers with early or unexpected mortality associated 
with psychiatric symptoms and abnormal move-
ments. The comparison of clinical variables between 
HD patients with and without family histories sh-
owed a delay in the onset of initial symptoms (p = 
0.047), a prolonged interval between initial symp-
tom onset and genetic diagnosis (p = 0.031) and a 
delay of the age at genetic diagnosis (p = 0.025) in 
those without a positive family history (Table 3). 
Neither the number of expanded CAG repeats nor 
the interval between the onset of chief complaints 
and hospital visit was different between the HD pa-
tients with and without family histories. 
DISCUSSION
To the best of our knowledge, this is the first study 
to estimate the prevalence and incidence of HD in 
Korea and the largest HD series of multi-center 
study in the Asian population. Most of the previous 
Asian epidemiologic studies of HD were performed 
on a regional basis, such as in Hong Kong, China or 
the San-in area of Japan.10,11 In Taiwan, the average 
annual incidence rate was estimated at 0.1 and the 
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Figure 1. Scatter plot for age of initial symptom onset and for the number of CAG repeats in expanded allele (A) 
and in normal allele (B). There is a significant decrease of age at initial symptom onset in accordance with the 
number of expanded CAG repeats based on a nonlinear regression model. The number of CAG repeats in normal 
allele has no correlation with the age at the initial symptom onset.
Figure 2. Occupation of the HD patients categorized based on the Korean stan-
dard classification of occupations, with modifications. The occupations of HD pa-
tients were evenly distributed across the category. Patient #: number of patients, 
HD: Huntington’s disease.
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prevalence at 0.42 per 100,000 persons, based on the 
National Health Insurance database.12 The annual 
incidence estimated in our study is about half of the 
average annual incidence of Taiwan; however, our 
estimate is similar to the annual incidence in China 
(0.046 per 100,000).10 Our estimation of the preva-
lence of HD in Korea based on two data sources 
was 0.41 per 100,000 in 2013 (Korean RDR) and 
0.38 per 100,000 bewteen 2009 to 2013 (National 
Health Insurance database), which are comparable 
to Taiwanese data and a meta-analysis.11,13 It is 
known that HD is less prevalent in Asian countries 
compared with Western countries, in which the 
overall prevalence is 5.70 according to a meta-anal-
ysis.13 Recent data suggests that the prevalence of 
HD may be over 10 per 100,000 in the UK.14 These 
racial differences in prevalence are accounted for by 
the differences in CAG tract size, HTT haplotype 
and CCG polymorphism.15-17 The mean CAG repeat 
length of the normal allele was reported to be sig-
nificantly longer in the European (18.4 ± 3.7) popu-
lation compared with the Chinese, Japanese, and 
Thai (16.4 ± 1.5, 16.6 ± 1.5, and 16.5 ± 1.9, respec-
tively) population.16,18 Furthermore, the distribution 
of CAG length was positively skewed in Europeans, 
which represents a length-dependent mutational 
bias towards longer alleles.19 In our collected dataset, 
we did not observe skewness in CAG length of nor-
mal alleles. The mean CAG repeat length of the 
normal allele in our HD patients was 17.4 ± 3.2, 
which is longer than that of other Asian popula-
tions, but shorter than that reported by a previous 
single center study in Korea20 and than those of West-
ern populations. Recently, HTT haplogroups (types 
A, B, and C) were identified, and CAG instability 
was more likely to occur in the cis-acting haplogroup 
A.15 HTT haplogroups are known to show a region-
al difference, and the higher risk haplotype was in-
frequent in China, Japan, and Thailand.18,21,22 The 
CCG polymorphic region is located adjacent to the 
CAG triplet repeat of the HD gene, and there is a 
linkage disequilibrium between CCG polymor-
phism and the pathological CAG expansion accord-
ing to the race.17,23 HTT haplogroup and CCG poly-
morphism have not yet been studied in Korean HD 
patients.
The mean age at initial symptom onset (44.16 ± 
14.08) and the inverse correlation between age at 
initial symptom onset and CAG repeat expansion 
size were compatible with previous reports.20,24-26 
The mean length of CAG repeats were similar to the 
previously reported range of 44.7 to 49.0 (range: 
36–70) in Korea and Western countries.5-7,20,27 More-
over, the length of the expanded CAG repeat deter-
mines the age of onset in approximately 50–70% of 
patients in the 40 to 55 CAG repeat range, but pos-
sible roles of other genetic and environmental mod-
ifiers are currently being investigated.28,29
Chorea is the most frequent initial symptom 
(60.3%) in our collected dataset as well as the chief 
complaint (85.3%), and the latter is compatible to 
the previously reported frequency (89%) at first visit 
to hospital.20 However, this finding also showed that 
approximately 40% of HD patients had initial symp-
toms other than chorea. Among the symptomatic 
triad of problems involving movement, cognition, 
and mood, the most prominent deficit may differ 
between patients, and recent studies have recog-
nized that non-motor symptoms occur before overt 
motor features in a fraction of patients.30,31
About one third of the patients comprising our 
collected dataset had no family history of HD, which 
is higher than reported in a study from British Co-
lumbia (29.8%)32 and in a previous report from a 
single center in Korea (20%).20 Given that the prob-
ability of de novo expansion of CAG repeats through 
Table 3. Differences according to the presence of family history
Clinical findings
Family history
p-value
Presence Absence
Age at initial symptom onset   41.81 ± 13.40   49.47 ± 14.49 0.047*
Interval between the age at initial symptom onset to the  
  genetic diagnosis (years)
  3.80 ± 2.71   5.58 ± 3.21 0.031*
Age at genetic diagnosis (years)   45.40 ± 13.64   54.11 ± 14.79 0.025*
Interval between the onset of chief complaint to hospital  
  visit (months)
  29.45 ± 23.76   43.59 ± 38.08 0.17
Number of expanded CAG repeat 45.30 ± 5.14 43.41 ± 3.64 0.18
Number of normal CAG repeat 17.28 ± 3.49 17.83 ± 2.48 0.62
*independent t test.
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paternal transmission was estimated to range from 
1/6,241 to 1/951,33 the higher rate of HD patients 
with a negative family history might not be ex-
plained solely by this mechanism. In addition to de 
novo expansion of CAG repeats, unstable familial 
transmission, reduced penetrance or underreported 
family history may be another cause of negative 
family history among HD patients.34-36 Interestingly, 
our HD patients without family history showed a 
delayed age at onset of initial symptoms, a delayed 
age at genetic diagnosis and a prolonged interval 
between the age of initial symptom onset to the age 
of genetic diagnosis compared with the HD patients 
with a positive family history. Lower CAG repeat 
number in negative family history groups may be 
related with these findings; however, a clinician’s de-
lay in suspicion of HD in choreic patients apparent-
ly lacking family history may have also contributed 
to this observation. Our study has some limitations. 
Because this research is based on retrospective chart 
review, extensive data gathering was impossible. 
Even after the diagnosis of HD, some patients may 
have refused to be registered into RDR because of 
social stigma and discrimination, which may have 
resulted in the underestimation of the real incidence 
and prevalence of HD.37
In conclusion, our estimated incidence and prev-
alence of HD were comparable with previous re-
ports of Asian populations and were relatively low 
compared with estimates for Western populations. 
The clinical features showed similar phenotypes, 
and the effect of CAG repeat expansion on the age 
of disease onset was comparable. Our analyses us-
ing national registries and multi-center clinical data 
could be useful for future studies and large-scale in-
vestigations in HD patients.
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